Pietro Fratta is Professor of Cellular and Molecular Neuroscience at the UCL Queen Square Institute of Neurology and the Francis Crick Institute. He previously worked at King’s College London, University of Southern California and San Raffaele Scientific Research Institute.

His laboratory combines patient tissue, iPSCs and mouse models to understand molecular disease mechanisms underlying ALS and neurodegeneration. Over the last five years, his laboratory has developed a novel gene therapy approach to limit therapeutic expression to diseased cells, uncovered the role of UNC13A in ALS and developed a splice-switching ASO therapeutics now brought forward by Trace Neuroscience, and identified novel biomarkers for ALS.

He is also a Consultant Neurologist at the National Hospital for Neurology and Neurosurgery in London, where he established National Kennedy’s Disease clinic and an MND Genetics clinic.